Key Drivers
- Profitability Rebound
- Negative Cash Flow
- Rising Leverage
AIAI Summary
TEM's investment case has shifted to a reimbursement-driven operating-leverage story, but at ~$80 investors should wait for proof that xT/xF reimbursement converts into sustained positive operating cash flow, as a shortfall in payer adoption or Personalis integration could sharply pressure its premium valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Profitability Rebound
- •Negative Cash Flow
- •Rising Leverage
TEM's profitability improved sharply in the latest quarter, but persistent cash burn, rising leverage, and a demanding valuation warrant caution despite strong liquidity.
Price Behavior
Key Price Behavior Insights:
- •Strong breakout
- •Resistance rejection
- •Key support
TEM gained 17% over the last month but faces pullback risk near $80–81 resistance, with $68–70 key support to hold.
Rapid rise to $80.36 followed by a pullback to $77.84
Sentiment & News
Key News Insights:
- •Analyst upgrades
- •ARPA-H funding
- •Valuation caution
Tempus AI's surge reflects analyst optimism, AI-healthcare catalysts and Merck-related momentum, though its rapid run-up raises near-term valuation risk.
Positive operational and partnership catalysts support sentiment, but elevated valuation may limit further near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings